Skip to main content
. 2016 Nov 16;10:3779–3787. doi: 10.2147/DDDT.S118145

Figure 3.

Figure 3

In vitro release profiles of PRX from drug powder, conventional and E30-NPs, and E30-NP/HA aggregates in 10 mM PBS solution at 37°C.

Notes: Vertical bars represent mean ± SD (n=3). E30-NPs, NPs prepared with PLGA and Eudragit RL at the weight ratio of 7:3.

Abbreviations: HA, hyaluronic acid; NPs, nanoparticles; PBS, phosphate-buffered saline; PLGA, poly(lactide-co-glycolic acid); PRX, piroxicam; SD, standard deviation.